Cytokinetics Announces Positive Topline Results of Redwood-HCM
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/24/2026
- Wall St futures retreat as oil gains on Mideast uncertainty, eyes on Trump-Xi talks
- Oil gains on little sign of progress in US-Iran talks
- S&P 500 history shows strong gains across Fed hiking cycles: BCA
- JPMorgan upgrades CoreWeave on stronger compute pricing
- BTIG’s Krinsky warns 2000-like signals are mounting
- Plug Power COO resigns to join another company
- Wall Street ends down as oil prices, Treasury yields rise
- Anthropic's Claude AI identifies novel enzyme system in DNA search
- AppLovin (APP) on watch amid 3% drop premarket as boutique comments circulate
- Xtend AI Robotics wins Phase III of USSOCOM lethal drone program
Cytokinetics' (CYTK) Redwood-HCM Top-line Results 'Deliver on All Fronts' - Analyst
July 19, 2021 1:58 PM EDTEarlier today, Cytokinetics, Inc (NASDAQ: CYTK) announced positive topline results from Cohorts 1 and 2 of Redwood-HCM - the Phase 2 clinical trial of CK-3773274 (CK-274), an investigational next-generation cardiac myosin inhibitor in development for the potential treatment of hypertrophic cardiomyopathy (HCM).
Throughout the trial, the CK-274 demonstrated high response rates, significant treatment effects and a favorable safety profile, reporting no serious adverse events attributable to CK-274 and no treatment interruptions occurring.
Reacting to the data readout, H.C. Wainwright & Co's analyst Joseph Pantginis believes the drug delivered on all fronts as expected and demonstrates... More
Cytokinetics (CYTK) PT Raised to $53 at H.C. Wainwright
July 19, 2021 12:27 PM EDTH.C. Wainwright analyst Joseph Pantginis raised the price target on Cytokinetics (NASDAQ: CYTK) to $53.00 (from $41.00) while maintaining a Buy rating.
... More